Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lipitor versus Zocor

This article was originally published in The Tan Sheet

Executive Summary

Patients who switched from Pfizer's Lipitor to simvastatin (Merck's Zocor and generics) had a statistically significant 30% increase in the relative risk of a major cardiovascular event or all-cause death than if they remained on atorvastatin, according to a large observational study presented Sept. 5 at the European Society of Cardiology Congress and slated for publication in the British Journal of Cardiology. The retrospective analysis was based on a comparison of records from a UK primary care database from October 1997 to June 2005 of 2,511 patients who had taken Lipitor for six months or more and switched to simvastatin and 9,009 patients who continued on Lipitor. A secondary analysis showed that patients who switched were more than twice as likely to discontinue therapy versus patients who remained on Lipitor (20.5% vs. 7.62%). Since the launch of generic simvastatin last year, market share growth for the generic has come primarily at the expense of Pfizer's Lipitor...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS100887

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel